What is Dr. Zubair Khalid's research focus?

Dr. Zubair Khalid specializes in molecular virology, mRNA vaccine development, and computational biology, with a focus on avian pathogens like IBDV and Avian Reovirus.

Where is Dr. Zubair Khalid currently working?

Dr. Zubair Khalid is a Postdoctoral Research Associate at the University of Maryland (UMD), specifically within the Department of Animal and Avian Sciences.

Do Koalas Get Chlamydia? Koala Chlamydia Explained

Name: Do Koalas Get Chlamydia? Koala Chlamydia Explained
Creator: Dr. Zubair Khalid

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-09-20

Yes, koalas get chlamydia. In fact, chlamydial infection is one of the most serious infectious threats facing koalas (Phascolarctos cinereus) across eastern Australia, and it is a leading driver of the species' decline in several regions [1][2]. The infection causes two signature problems: blinding eye disease and reproductive tract disease that leaves many animals infertile.

The single most common misconception is that koala chlamydia is the same infection people get. It is not. Koalas carry Chlamydia pecorum and Chlamydia pneumoniae, which are different bacterial species from the Chlamydia trachomatis serovars that cause human sexually transmitted infection and trachoma. That distinction has practical consequences for anyone who handles koalas, and it is the first thing to get straight before looking at transmission, disease, or vaccines.

This article is educational and is not a substitute for veterinary diagnosis or treatment.

The Organisms: Koala Chlamydia Is Not Human Chlamydia

Chlamydiae are obligate intracellular bacteria. They cannot survive and multiply outside a host cell, which shapes everything about how they spread and how they are treated.

Chlamydia pecorum is the major chlamydial pathogen of koalas, in both wild and captive settings [2]. It also infects livestock, notably ruminants, and comparative genomics work has shown clear biogeographic separation between strains infecting northern and southern koala populations, and between strains from koala and livestock hosts [3]. That means the koala is not simply picking up a cattle bacterium. The strains circulating in koalas have their own evolutionary trajectory, and the host-pathogen relationship appears to be relatively recent in evolutionary terms [4].

Chlamydia pneumoniae also infects koalas, though it is a less prominent cause of the classic blinding and infertility syndrome than C. pecorum [2]. In people, C. pneumoniae is a respiratory pathogen. In koalas, the same species can be found in the respiratory tract and has been associated with disease, but it is not the organism that defines koala chlamydiosis.

The table below places the relevant chlamydial species side by side.

Chlamydia species	Primary host(s)	Typical disease in that host
C. pecorum	Koalas, cattle, sheep, other ruminants, swine	Ocular disease (conjunctivitis, keratitis, blindness) and urogenital disease (infertility, urinary tract disease) in koalas. Enteric and reproductive disease in livestock.
C. pneumoniae	Humans, koalas, other mammals	Respiratory infection in humans. Respiratory and occasionally ocular involvement in koalas.
C. trachomatis	Humans	Trachoma (blinding eye disease) and sexually transmitted urogenital infection in humans.
C. psittaci	Birds, humans, other mammals	Avian chlamydiosis, and psittacosis in humans after exposure to infected birds.
C. abortus	Sheep, goats, cattle	Enzootic abortion in ruminants.

The practical takeaway from that table is simple. A koala with chlamydia is carrying a koala-adapted strain of C. pecorum or C. pneumoniae, not the human STI organism. There is no documented pathway by which a person catches C. trachomatis from a koala, because the koala is not a host for that organism.

How Common Is Chlamydia in Koalas?

Prevalence varies enormously by geography, age, and sex, and it can be very high in some populations.

A 2026 study of 285 koalas across two neighboring regions of Southeast Queensland found C. pecorum in 32% of animals overall, with disease present in 24% [5]. Within that same dataset, infection prevalence was significantly higher in the northern study region at 46%, compared with 17% in the southern region, and disease prevalence was 25% versus 11% [5]. Among koalas that were infected, 57% showed clinical disease [5]. Infection was more frequent in adult males than females, at 54% versus 37% [5].

Those regional figures matter because they show how misleading a single national number would be. In some Queensland populations, prevalence has been reported above 50%, and the pattern of high-burden northern populations and lower-burden southern populations recurs across the literature [5][3]. Age and geographic location were significant predictors of infection, and age, body condition, and infection status predicted whether an infected koala developed clinical disease [5].

A separate co-infection study of 115 wild koalas admitted to wildlife hospitals in Queensland and New South Wales detected C. pecorum in 61.1% of individuals [6]. That is a hospital-admitted sample, so it over-represents sick animals, but it illustrates how heavily chlamydia features in the koalas that reach veterinary care.

How Koalas Get Chlamydia

Transmission of C. pecorum between koalas occurs through direct contact and through contaminated environments. Two routes dominate.

Sexual transmission

Sexual contact is a major route. Infected males shed the organism from the urogenital tract, and mating transmits infection to females. The male reproductive tract is a significant reservoir, and pathology in the testis and epididymis is well documented in naturally infected males [7]. Because male reproductive tract disease is difficult to diagnose reliably on physical examination, sex is often excluded from disease models to avoid bias, even though infection prevalence is higher in males [5].

Pap feeding

Pap feeding is the second key route, and it is unique to koalas. A mother produces a soft fecal material called pap and feeds it to her joey to inoculate the gut with the microbes needed to digest eucalyptus. If the mother is shedding C. pecorum, the pap can carry the organism to the joey [2]. This is how infection passes from one generation to the next, and it explains why joeys can be infected without any sexual contact.

Environmental and fomite transmission

Chlamydial DNA contaminates shared equipment and surfaces in koala care settings. A biosecurity study swabbed fomite sites at a New South Wales koala rehabilitation facility after exposure to known infected koalas and again after decontamination [8]. Of 239 sampling events, 30 tested positive for chlamydial DNA by qPCR, with 19 positives before decontamination and 11 after [8]. Detection was most common in the examination room, particularly on surfaces in direct contact with animals [8].

That finding has two implications. First, koalas held in proximity during capture or rehabilitation are at real risk of cross-infection, which is why quarantine and disinfection protocols matter [8]. Second, finding DNA after cleaning does not automatically mean viable infectious organisms remain, which is why the same study paired DNA detection with viability testing using RT-qPCR and cell culture [8].

What Chlamydia Does to a Koala

The disease koalas develop from C. pecorum has two main faces, ocular and urogenital, and both can be devastating.

Ocular disease and blindness

Chlamydial conjunctivitis is the classic eye presentation. The conjunctiva becomes inflamed, the eye discharges, and the cornea can become involved. Progression leads to keratitis and, in severe cases, blindness [9][5]. Blindness is not just a welfare problem. A blind koala cannot find food reliably, cannot avoid predators or vehicles, and cannot navigate the trees it depends on.

Reproductive tract disease and infertility

The urogenital tract is where chlamydia does its most consequential damage to koala populations. In females, infection causes inflammation and scarring of the reproductive tract that leads to infertility. In males, the picture is now well characterized. A study of 58 sexually mature male koalas assessed semen quality, sperm DNA quality, and testosterone secretion, alongside histopathology and qPCR of testis, epididymis, and prostate tissue [7]. Males with unilateral or bilateral testicular atrophy and C. pecorum infection showed a significant difference in sperm concentration [7]. Earlier work in the same line of research found that males with severe urogenital chlamydial disease had increased sperm DNA fragmentation and abnormal sperm morphology, consistent with chronic infection and inflammation disrupting spermatogenesis and sperm maturation [7].

The population-level consequence is straightforward. A disease that blinds and sterilizes a slow-breeding marsupial removes individuals from the breeding pool and reduces fecundity across the population [10]. That is why chlamydiosis is treated as a conservation emergency and not just a clinical problem.

Co-infections change the picture

Koalas rarely carry only one pathogen. A study of 115 wild koalas found C. pecorum in 61.1%, phascolarctid herpesvirus in 68.9%, trypanosomes in 63.3%, and koala retrovirus in 100% of sampled individuals [6]. Among koalas with chlamydiosis, mucosal shedding of PhaHV-1 positively predicted euthanasia on admission, and in female koalas, mucosal PhaHV-1 detection and higher KoRV proviral loads were equal predictors of chlamydial reproductive disease [6].

Koala retrovirus (KoRV) deserves separate mention because of how often it is invoked as an explanation for koala chlamydia severity. A 2025 study tracked KoRV plasma RNA load over a year in relation to chlamydia and stress hormones [11]. KoRV load was stable within individual koalas over time and did not rise when a koala began shedding C. pecorum, nor fall when the animal cleared the infection through self-clearance or treatment [11]. Koalas treated for chlamydiosis maintained higher KoRV loads than healthy counterparts [11]. Higher average KoRV loads correlated with higher average fecal glucocorticoid metabolite levels [11].

The honest reading of that evidence is that KoRV and chlamydia are entangled but the causal direction is not settled. KoRV does not appear to spike simply because chlamydia appears.

Diagnosis in Koalas

Diagnosis in wild and hospitalized koalas relies on molecular detection from swabs, most often ocular and urogenital, combined with veterinary examination for clinical signs [5][12].

There is no single standardized diagnostic approach across wildlife hospitals, and test performance has only recently been assessed rigorously. A 2026 study used Bayesian latent class analysis to compare four molecular assays for C. pecorum in koalas, including a 16S rRNA qPCR with melt curve, an ompB probe-based qPCR, and two loop-mediated isothermal amplification (LAMP) assays [12]. The 16S rRNA qPCR and one of the LAMP assays (targeting CpecG_0573) showed the highest overall diagnostic accuracy, with Youden's indices of 83.8% and 81.5% respectively [12].

Non-invasive sampling is advancing. A 2024 study combined restriction-enzyme associated sequencing with targeted sequence capture to detect C. pecorum in koala scats, achieving 91.7% sensitivity and 100% specificity compared with qPCR of swab samples [13]. Scat-based testing allows large-scale surveillance without capturing and anesthetizing animals, which matters for a threatened species [13].

For a US audience, the relevance is indirect but real. If you encounter a koala in a zoo, sanctuary, or wildlife park, diagnosis and management are handled by the facility's veterinarians under Australian wildlife protocols. There is no home testing pathway and no role for human chlamydia tests.

Treatment Options and Their Limits

Antibiotics can treat chlamydial infection in koalas, but they are not a clean solution. The koala gut depends on a specialized microbiome to detoxify eucalyptus compounds, and antibiotic therapy can cause severe dysbiosis to that unique gut flora [9]. Treatment is also often incompletely effective, and treated koalas may remain carriers or relapse [11].

This is the core reason vaccine development has become the central research priority. A vaccine that prevents infection or reduces disease severity would avoid the collateral damage of antibiotics and would be deployable at population scale, which antibiotics are not.

Vaccine Research: Where It Stands

Koala chlamydia vaccine research has produced both encouraging and disappointing results, and the field has learned from both. Koalas are now the first wildlife species with a conditionally approved C. pecorum vaccine, approved under Australia's veterinary minor-use pathway based on real-world evidence rather than controlled challenge studies [14].

Single-dose vaccine trials

A 2017 study immunized a wild koala population with one of two single-dose recombinant vaccines, one based on Major Outer Membrane Protein (3MOMP) and one based on Polymorphic Membrane Protein (Pmp) [15]. Both vaccines produced anti-chlamydial IgG antibodies in more than 90% of vaccinated koalas, with mucosal IgG and/or IgA responses in some animals and cell-mediated cytokine responses (IFN-γ and IL-17) after vaccination [15]. The protection results diverged sharply. Koalas vaccinated with the MOMP vaccine that were already infected on the day of vaccination showed significant clearance of their infection at 6 months post-vaccination, while the PMP vaccine produced new infection rates similar to controls, with some koalas progressing to disease [15].

A 2016 study examined whether vaccination could help koalas that already had clinical ocular disease, and reported a positive effect, suggesting a possible therapeutic role and an alternative to antibiotic therapy [9].

Two-dose regimens and later formulations

The current vaccine requires a booster dose to achieve optimal immune protection [16]. That requirement creates a practical problem in the wild, because every booster means recapturing the animal. A 2026 study assessed whether the MOMP antigen used in the vaccine remains stable and antigenic after six weeks at 37 °C, which is the temperature it would experience inside a delayed-release implant [16]. Aged MOMP induced antibody responses comparable to unaged antigen, supporting the feasibility of an implant that delivers the booster without recapture [16].

Not every formulation has worked. A 2023 trial of a synthetic peptide vaccine based on four components of C. pecorum MOMP, followed over 18 months in a koala population severely affected by chlamydiosis, found no effect. Vaccination did not alter clinical disease expression or chlamydial shedding from ocular or urogenital sites, did not stimulate a significant plasma anti-MOMP IgG response compared with placebo, and did not significantly affect IFN-γ or IL-17A mRNA expression [10]. The authors concluded that synthetic peptide vaccination was not an effective management tool in that high-prevalence population [10].

A separate 2023 study tested a novel peptide version of the chlamydia vaccine and a combination chlamydia plus KoRV vaccine in a monitored wild population in Southeast Queensland over 17 months [17]. Both formulations resulted in a decrease in chlamydiosis mortality, with decreases in C. pecorum, CD4, CD8β, and IL-17A gene expression observed [17].

The most recent population-level trial

The most rigorous recent test came in 2025, when researchers ran a blinded, randomized, placebo-controlled trial of a C. pecorum recombinant MOMP vaccine across wild koala populations with differing chlamydiosis burdens, following animals for 12 months with recapture at 2, 6, and 12 months [18]. Vaccination stimulated a significant plasma anti-MOMP IgG response and greater IL-17 and TNFα mRNA fold change from rMOMP-stimulated leukocytes, but did not boost pre-existing immune responses from natural infection [18]. Critically, the immunological stimulation did not translate into any effect on chlamydiosis or chlamydial shedding in the study populations [18]. The authors concluded that a better understanding of what constitutes a protective immune response in koalas is needed to guide a more effective vaccine [18].

That result is a setback, not a dead end. It tells the field that measurable antibody and cytokine responses are not sufficient proxies for protection, and that the koala immune correlate of protection remains unidentified [18][14].

Why the koala vaccine matters beyond koalas

The koala vaccine program has a broader scientific value. Chlamydia trachomatis still has no licensed human vaccine, and human efforts are slowed by uncertain immune correlates, asymptomatic infection, difficult licensure endpoints, and limited commercial incentive [14]. Koalas share those constraints, but their visible ocular and urogenital disease allows clinical assessment under natural infection conditions [14]. The koala is therefore functioning as a natural-host model for intracellular pathogen vaccinology [14].

What Is Still Uncertain

Several important questions remain open.

The immune correlate of protection in koalas is not known, which is the central obstacle to a better vaccine [18][14]. Why some infected koalas clear infection and others progress to severe disease is not fully explained [5]. The contribution of co-pathogens, including KoRV, phascolarctid herpesvirus, and trypanosomes, to chlamydial disease outcomes requires further work [6]. C. pecorum genomic data remain sparse, with only seven complete genomes available, which limits strain-level vaccine matching [1]. The significance of C. pecorum in non-koala marsupials, other wildlife, and additional domestic animals is unclear [1].

On the epidemiology side, strain movement between fragmented koala habitats is an active concern. A 2024 genotyping study of two New South Wales populations documented suspected recent introduction of a novel strain into the Liverpool Plains population and movement of a strain from a diverse southern region into a previously chlamydia-free area in the north of the Southern Highlands to South-west Sydney region, indicating risk of expansion toward an adjacent chlamydia-negative koala population [19]. Fragmentation appears to hinder but not prevent strain spread [19].

Practical Implications for People Who Work With Koalas

For zoo and sanctuary staff, wildlife rehabilitators, and researchers, the operational priorities are consistent with the evidence.

Quarantine and disinfection protocols in koala care settings are not optional. Environmental contamination with chlamydial DNA is documented on fomites, particularly in examination rooms [8]. Shared equipment between animals should be treated as a transmission risk [8].

Recapture logistics shape vaccine strategy. Because the current vaccine requires a booster, and wild koalas are difficult to recapture repeatedly, delayed-release implant technology is being developed specifically to solve this problem [16].

Antibiotic use carries a real cost to the koala gut microbiome, which is why vaccination is pursued as an alternative rather than a supplement to antibiotics [9].

For the general public, the message is reassurance. Koala chlamydia is not a human STI risk. There is no C. trachomatis transmission pathway from koalas to people.

Limitations and When to Contact a Veterinarian

This article is educational and is not a substitute for veterinary diagnosis or treatment.

If you work with or handle koalas in any capacity and observe ocular discharge, conjunctival redness, cloudiness of the eye, visible urogenital swelling or discharge, or a decline in body condition, contact the facility's veterinarian or the relevant wildlife authority immediately. These signs are consistent with chlamydial disease and warrant prompt diagnostic testing [5][12].

If you are involved in koala rehabilitation or captive care, escalate to a veterinarian if an animal develops new ocular signs, if urogenital signs appear or worsen, if an animal that was previously testing negative begins shedding, or if a koala in your care dies unexpectedly, since co-infections such as phascolarctid herpesvirus are associated with worse outcomes [6].

Any individual koala's diagnosis, prognosis, and treatment plan require direct veterinary assessment. Population-level statistics and vaccine trial results do not predict what will happen to a specific animal.

Frequently Asked Questions

Do koalas get chlamydia?

Yes. Koalas are commonly infected with Chlamydia pecorum, and to a lesser extent Chlamydia pneumoniae, and chlamydial disease is a major threat to koala populations in eastern Australia [1][2].

Can humans get chlamydia from koalas?

No. Koalas carry C. pecorum and C. pneumoniae, not the C. trachomatis serovars that cause human sexually transmitted infection, so there is no human transmission pathway from koalas [2].

Do koalas carry chlamydia without showing symptoms?

Yes. Infection and disease are not the same thing, and many infected koalas show no clinical signs. In one Queensland dataset, 32% of koalas were infected but only 24% had disease [5].

How do koalas get chlamydia?

The two main routes are sexual contact between adults and pap feeding, in which an infected mother passes the organism to her joey through the soft fecal material used to inoculate the joey's gut [2]. Contaminated equipment and surfaces in care settings are an additional risk [8].

Does chlamydia make koalas blind?

Yes, in severe cases. Chlamydial conjunctivitis can progress to corneal involvement and blindness, and ocular disease is one of the two signature presentations of koala chlamydiosis [9][5].

Can chlamydia make koalas infertile?

Yes. Chlamydial infection of the reproductive tract causes inflammation and pathology that leads to infertility in females and to impaired sperm quality and testicular atrophy in males [7][9].

Is there a vaccine for koala chlamydia?

Yes, a C. pecorum vaccine has received conditional approval in Australia under the veterinary minor-use pathway [14]. Results across trials have been mixed, with some formulations reducing mortality and others showing no effect on disease or shedding [18][17].

What percentage of koalas have chlamydia?

Prevalence varies widely by region. A 2026 Southeast Queensland study found 32% overall, ranging from 17% in the southern region to 46% in the northern region, and some Queensland populations exceed 50% [5].